0
0
3/27/22 at 6:35pm
Organization
Hcplive.com
Author
Kevin Kunzmann
36 words
0
Comments
The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.
You are the first to view
https://www.hcplive.com/view/dupilumab-biologics-youngest-atopic-dermatitis-patients
Create an account
or login to join the discussion